Profil
Oliver Reuß has worked as an Executive Director & Investment Manager at Boehringer Ingelheim (Venture Capital) since 2018.
He is also currently a Director at Brainomix Ltd.
Postes actifs de Oliver Reuß
| Sociétés | Poste | Début |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Private Equity Investor | 01/05/2018 |
Brainomix Ltd.
 Brainomix Ltd. BiotechnologyHealth Technology Brainomix Ltd. develops imaging biomarkers for neurological and cerebrovascular disorders. It offers e-ASPECTS, medical imaging software that automates a scoring system on brain images from acute ischaemic stroke patients to identify and quantify signs of early stroke damage and assist the physician's decision to treat. The company founded by Michalis Papadakis, Alastair Buchan, Iris Grunwald, Constantin Thiopoulos, and Michael Printzos in 2010 and is headquartered in Oxford, the United Kingdom. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Finance |
Brainomix Ltd.
Brainomix Ltd. BiotechnologyHealth Technology Brainomix Ltd. develops imaging biomarkers for neurological and cerebrovascular disorders. It offers e-ASPECTS, medical imaging software that automates a scoring system on brain images from acute ischaemic stroke patients to identify and quantify signs of early stroke damage and assist the physician's decision to treat. The company founded by Michalis Papadakis, Alastair Buchan, Iris Grunwald, Constantin Thiopoulos, and Michael Printzos in 2010 and is headquartered in Oxford, the United Kingdom. | Health Technology |